Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly

被引:61
作者
Holla, Oystein L. [1 ]
Cameron, Jamie [1 ]
Berge, Knut Erik [1 ]
Ranheim, Trine [1 ]
Leren, Trond P. [1 ]
机构
[1] Rikshosp Radiumhosp Med Ctr, Dept Med Genet, Med Genet Lab, Oslo, Norway
关键词
D O I
10.1186/1471-2121-8-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) post-transcriptionally degrades the low density lipoprotein receptors (LDLR). However, it is unknown whether PCSK9 acts directly on the LDLR or if PCSK9 activates another protein that in turn causes degradation of the LDLR. Results: We have transiently transfected HepG2 cells with wild-type and mutant D374Y-PCSK9 plasmids to study the effect of the conditioned medium on the LDLR of untransfected HepG2 cells. The ability of the conditioned medium to reduce the internalization of LDL was abolished by removal of recombinant PCSK9 from the conditioned medium by affinity chromatography. Thus, PCSK9 is the only factor in the conditioned medium able to mediate degradation of the LDLR. Moreover, fractionation of the conditioned medium by gel filtration showed that the ability of the fractions to reduce the internalization of LDL, closely paralleled the amount of D374Y-PCSK9 in the fractions. Incubation of a secreted, truncated LDLR without cytoplasmic and transmembrane domains, as well as membrane fractions from HepG2 cells, with conditioned medium containing PCSK9, did not reduce the amount of LDLR as determined by western blot analysis. Thus, the LDLR is not degraded by PCSK9 on the cell surface. The LDLR of HepG2 cells incubated with conditioned medium was protected from PCSK9-mediated degradation by the addition of nocodazole or ammonium chloride, but was not protected when the conditioned medium was made hypertonic. These findings indicate that the intracellular degradation of the LDLR involves intracellular transport along microtubules, an acidic intracellular compartment and that it occurs even when endocytosis through clathrin-coated pits has been blocked. Conclusion: Degradation of the LDLR by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. Also the PCSK9-mediated degradation of the LDLR does not take place on the cell surface. Rather, the PCSK9-mediated degradation of the LDLR appears to take place intracellularly and occurs even when endocytosis through clathrin-coated pits is blocked by hypertonic medium.
引用
收藏
页数:12
相关论文
共 29 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] Allard Delphine, 2005, Hum Mutat, V26, P497, DOI 10.1002/humu.9383
  • [3] NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
    Benjannet, S
    Rhainds, D
    Essalmani, R
    Mayne, J
    Wickham, L
    Jin, WJ
    Asselin, MC
    Hamelin, J
    Varret, M
    Allard, D
    Trillard, M
    Abifadel, M
    Tebon, A
    Attie, AD
    Rader, DJ
    Boileau, C
    Brissette, L
    Chrétien, M
    Prat, A
    Seidah, NG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) : 48865 - 48875
  • [4] The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
    Benjannet, Suzanne
    Rhainds, David
    Hamelin, Josee
    Nassoury, Nasha
    Seidah, Nabil G.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (41) : 30561 - 30572
  • [5] Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
    Berge, KE
    Ose, L
    Leren, TP
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : 1094 - 1100
  • [6] Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
    Cameron, J
    Holla, OL
    Ranheim, T
    Kulseth, MA
    Berge, KE
    Leren, TP
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 (09) : 1551 - 1558
  • [7] Low LDL cholesterol in African Americans resulting from frequent nonsense mutations in PCSK9
    Cohen, J
    Pertsemlidis, A
    Kotowski, IK
    Graham, R
    Garcia, CK
    Hobbs, HH
    [J]. NATURE GENETICS, 2005, 37 (03) : 328 - 328
  • [8] Expression and localization of PCSK9 in rat hepatic cells
    Grozdanov, PN
    Petkov, PM
    Karagyozov, LK
    Dabeva, MD
    [J]. BIOCHEMISTRY AND CELL BIOLOGY, 2006, 84 (01) : 80 - 92
  • [9] MOLECULES INTERNALIZED BY CLATHRIN-INDEPENDENT ENDOCYTOSIS ARE DELIVERED TO ENDOSOMES CONTAINING TRANSFERRIN RECEPTORS
    HANSEN, SH
    SANDVIG, K
    VANDEURS, B
    [J]. JOURNAL OF CELL BIOLOGY, 1993, 123 (01) : 89 - 97
  • [10] HYPERTONIC MEDIA INHIBIT RECEPTOR-MEDIATED ENDOCYTOSIS BY BLOCKING CLATHRIN-COATED PIT FORMATION
    HEUSER, JE
    ANDERSON, RGW
    [J]. JOURNAL OF CELL BIOLOGY, 1989, 108 (02) : 389 - 400